ABEO Overview

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).

Wall Street analysts forecast ABEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABEO is25.17 USD with a low forecast of 20.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Abeona Therapeutics Inc revenue for the last quarter amounts to 5.42M USD, decreased

Abeona Therapeutics Inc. EPS for the last quarter amounts to -0.37 USD, increased 94.74

Abeona Therapeutics Inc (ABEO) has 226 emplpoyees as of March 31 2026.

Today ABEO has the market capitalization of 241.32M USD.